We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius ... Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Show more
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire CRANFORD, N.J., Sept. 5, 2024 CEO Leonard Mazur to present on Tuesday, September...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIRβ’ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.023 | 4.50980392157 | 0.51 | 0.61 | 0.5009 | 1436811 | 0.54756112 | CS |
4 | -0.126 | -19.1198786039 | 0.659 | 0.665 | 0.48 | 851138 | 0.5469255 | CS |
12 | -0.026 | -4.6511627907 | 0.559 | 1.05 | 0.48 | 1930198 | 0.75224435 | CS |
26 | -0.247 | -31.6666666667 | 0.78 | 1.07 | 0.48 | 1851564 | 0.72685119 | CS |
52 | -0.167 | -23.8571428571 | 0.7 | 1.07 | 0.48 | 1226411 | 0.72982068 | CS |
156 | -1.617 | -75.2093023256 | 2.15 | 2.2499 | 0.48 | 1269390 | 1.15213854 | CS |
260 | -0.3168 | -37.2793598494 | 0.8498 | 4.56 | 0.4 | 2402488 | 1.74982548 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions